Calyx and lender agree to extend portion of convertible loan



    NORTH VANCOUVER, Oct. 29 /CNW/ - Calyx Bio-Ventures Inc. ("Calyx" or the
"Company") announced today that the Company has repaid to W. Hugh Notman
$200,000 of the $400,000 principal amount owing, together with interest
accrued to September 30, 2008, on the secured, convertible debenture
previously issued by Chromos Molecular Systems Inc. ("Chromos"), the former
parent of Calyx, to Mr. Notman. This debenture was assigned to, and assumed
by, Calyx as part of the recently completed plan of arrangement and related
transactions involving, among others, Calyx and Chromos. The maturity date for
the balance of the principal amount owing has been extended to November 14,
2008.

    Forward-Looking Statements

    Certain statements in this news release may contain "forward-looking
statements" or "forward-looking information" within the meaning of applicable
securities legislation Often, but not always, forward-looking statements or
information can be identified by the use of words such as "plans", "expects"
or "does not expect", "is expected", "budget", "scheduled", "estimates",
"forecasts", "intends", "anticipates" or "does not anticipate", or "believes"
or variations of such words and phrases or words and phrases that state or
indicate that certain actions, events or results "may", "could", "would",
"might" or "will" be taken, occur or be achieved. With respect to
forward-looking statements and information contained herein, we have made
numerous assumptions. Although our management believes that the assumptions
made and the expectations represented by such statements or information are
reasonable, there can be no assurance that a forward-looking statement or
information herein will prove to be accurate. Forward-looking statements and
information by their nature are based on assumptions and involve known and
unknown risks, uncertainties and other factors which may cause our actual
results, performance or achievements, or industry results, to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. Should one or more of these risks
and uncertainties materialize, or should the underlying assumptions prove
incorrect, actual results may vary materially from those described in
forward-looking statements and information.
    Although we have attempted to identify factors that may cause actual
actions, events or results to differ materially from those described in
forward-looking statements and information, there may be other factors that
cause actual results, performances, achievements or events to not be as
anticipated, estimated or intended. Also, many of the factors are beyond our
control. As actual results and future events could differ materially from
those anticipated in such statements and information, readers should not place
undue reliance on forward-looking statements or information. Except as may be
required by law, we undertake no obligation to publicly update or revise any
forward-looking statements or information, whether as a result of new
information, future events or otherwise. All forward-looking statements and
information made herein are qualified by this cautionary statement.

    
    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this release.
    





For further information:

For further information: Roger Flowerdew, CA, CEO and President, (604)
985-7100

Organization Profile

CALYX BIO-VENTURES INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890